Study of pre-surgery drugs for head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests two medications given before surgery for head and neck cancer. The goal is to see if shrinking the tumor beforehand improves outcomes. If you have operable head and neck squamous cell cancer and are generally healthy, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of head and neck cancer (squamous cell) that can be removed with surgery
- Your cancer is not in the nasopharynx, salivary glands, or thyroid
- You are in generally good health with adequate organ function (blood counts, liver, kidneys)
- You have not had certain prior cancer treatments or other cancers in the last 5 years
- You do not have an active autoimmune disease or severe drug allergies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
Hear when a new Resectable Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.